Shares of MEI Pharma, Inc. (NASDAQ:MEIP – Get Rating) have been given a consensus rating of “Hold” by the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $2.50.
MEIP has been the subject of a number of recent analyst reports. Truist Financial lowered shares of MEI Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, December 6th. StockNews.com initiated coverage on shares of MEI Pharma in a report on Thursday, January 12th. They set a “hold” rating for the company. Finally, BTIG Research lowered shares of MEI Pharma from a “buy” rating to a “neutral” rating in a report on Tuesday, December 6th.
MEI Pharma Stock Performance
MEIP opened at $0.33 on Thursday. The company has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.41. The firm has a market cap of $44.24 million, a price-to-earnings ratio of -0.83 and a beta of 0.93. MEI Pharma has a twelve month low of $0.21 and a twelve month high of $2.37.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Two Sigma Investments LP lifted its position in MEI Pharma by 50.4% in the 3rd quarter. Two Sigma Investments LP now owns 379,011 shares of the company’s stock valued at $147,000 after purchasing an additional 127,046 shares during the last quarter. Vanguard Group Inc. lifted its position in MEI Pharma by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,668,708 shares of the company’s stock valued at $2,965,000 after purchasing an additional 322,969 shares during the last quarter. Carlson Capital L P lifted its position in MEI Pharma by 4.5% in the 3rd quarter. Carlson Capital L P now owns 1,150,000 shares of the company’s stock valued at $445,000 after purchasing an additional 50,000 shares during the last quarter. Annandale Capital LLC bought a new stake in MEI Pharma in the 3rd quarter valued at about $39,000. Finally, Zacks Investment Management bought a new stake in MEI Pharma in the 3rd quarter valued at about $42,000. 35.74% of the stock is currently owned by institutional investors.
About MEI Pharma
MEI Pharma, Inc is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on MEI Pharma (MEIP)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.